These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 23592350)
1. Oral therapy approved for multiple sclerosis. Traynor K Am J Health Syst Pharm; 2013 May; 70(9):744. PubMed ID: 23592350 [No Abstract] [Full Text] [Related]
2. The New England Journal of Medicine publishes pivotal data demonstrating efficacy and safety of oral BG-12 (dimethyl fumarate) in multiple sclerosis. Fox R Can J Neurosci Nurs; 2012; 34(3):7-11. PubMed ID: 23362583 [No Abstract] [Full Text] [Related]
3. Trial watch: Phase III success for Biogen's oral multiple sclerosis therapy. Nat Rev Drug Discov; 2011 Jun; 10(6):404. PubMed ID: 21629281 [No Abstract] [Full Text] [Related]
4. Recognizing and overcoming potential barriers to oral medications for MS. Moses H J Clin Psychiatry; 2014 Oct; 75(10):e28. PubMed ID: 25373133 [TBL] [Abstract][Full Text] [Related]
5. Diroximel fumarate to treat multiple sclerosis. Wang Y; Bhargava P Drugs Today (Barc); 2020 Jul; 56(7):431-437. PubMed ID: 32648853 [TBL] [Abstract][Full Text] [Related]
6. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis. Thomas RH; Wakefield RA Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835 [TBL] [Abstract][Full Text] [Related]
7. Dimethyl fumarate (Tecfidera) for multiple sclerosis. Med Lett Drugs Ther; 2013 Jun; 55(1418):45-7. PubMed ID: 24662841 [No Abstract] [Full Text] [Related]
8. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Venci JV; Gandhi MA Ann Pharmacother; 2013 Dec; 47(12):1697-702. PubMed ID: 24259625 [TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis: Dimethyl fumarate is coming of age. Tintoré M; Sastre-Garriga J Nat Rev Neurol; 2016 Aug; 12(8):436-7. PubMed ID: 27448183 [No Abstract] [Full Text] [Related]
16. Dimethyl fumarate induced migrating polyarthralgias. Villedon de Naide M; Moisset X; Soubrier M Joint Bone Spine; 2019 May; 86(3):399-400. PubMed ID: 30081200 [No Abstract] [Full Text] [Related]
17. Response to comment on "Dimethyl fumarate (tecfidera): a new oral agent for multiple sclerosis". Venci J; Gandhi MA Ann Pharmacother; 2014 Nov; 48(11):1537. PubMed ID: 25301830 [No Abstract] [Full Text] [Related]
18. [Emerging therapies for multiple sclerosis]. de Lorenzo-Pinto A; Rodríguez-González CG; Ais-Larisgoitia A Med Clin (Barc); 2013 Jan; 140(2):76-82. PubMed ID: 22766059 [TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070 [TBL] [Abstract][Full Text] [Related]
20. Lorcaserin, dimethyl fumarate, and bedaquiline fumarate. Hussar DA; Polyak G J Am Pharm Assoc (2003); 2013; 53(3):328-30, 332, 334. PubMed ID: 23699683 [No Abstract] [Full Text] [Related] [Next] [New Search]